Hong Kong Pharma Stock News

MicroPort Scientific reported full-year 2025 sales of US$994.91 million and net income of US$48.52 million, while announcing that long-time chairman Dr. Zhaohua Chang stepped down as CEO and was replaced by rotating chief executive Jonathan W. Chen alongside the creation of a new Global Executive Committee and a new company secretary. This combination of a turnaround to profitability with a refreshed leadership and governance structure highlights MicroPort Scientific’s push to align...

Kuaishou Technology (SEHK:1024) shares moved after the company reported quarterly and full year 2025 earnings, together with a recommended final dividend, giving investors fresh data on cash generation, shareholder returns and recent business performance. See our latest analysis for Kuaishou Technology. The latest 4.01% 1 day share price return, to HK$46.7, comes after a tougher few months, with a 30 day share price return of 22.87% decline and a 90 day share price return of 35.05% decline...

Air China has launched a new direct passenger route between Chengdu and Brussels, creating a fresh air link between China and Belgium. The service is intended to support international connectivity and contribute to the recovery of inbound tourism in Chengdu. The new route forms part of Air China’s wider international network development and aligns with local infrastructure and travel facilitation efforts. For investors tracking Air China (SEHK:753), the new Chengdu to Brussels route lands...

China Mengniu Dairy (SEHK:2319) has come into focus after releasing its full year 2025 results and proposing a final ordinary dividend of RMB 0.52 per share, subject to shareholder approval. See our latest analysis for China Mengniu Dairy. The latest earnings and dividend proposal appear to have supported sentiment, with a 30 day share price return of 6.36% and a 90 day share price return of 14.41% lifting the stock to HK$17.55. This comes even though the 1 year total shareholder return is a...

Simcere Pharmaceutical Group (SEHK:2096) has drawn fresh attention after reporting full year 2025 sales of CN¥7,731.41 million and net income of CN¥1,344.01 million, alongside a proposed final dividend of CN¥0.18 per share. See our latest analysis for Simcere Pharmaceutical Group. At a latest share price of HK$13.62, Simcere Pharmaceutical Group has seen a 16.91% 1 month share price return and an 80.98% 1 year total shareholder return. Recent earnings, dividend and leadership announcements...

Today is shaping up negative for Contiocean Environment Tech Group Co., Ltd. ( HKG:2613 ) shareholders, with the...

Sinotruk (Hong Kong) (SEHK:3808) has drawn fresh attention after reporting full year 2025 results with higher sales and net income, along with a board proposal to lift the ordinary final dividend for shareholders. See our latest analysis for Sinotruk (Hong Kong). The share price has responded strongly, with a 30 day share price return of 14.48% and a 90 day gain of 51.71%. The 1 year total shareholder return of 137.59% points to building momentum around the healthier earnings and higher...

Ubtech Robotics Corp Ltd ( HKG:9880 ) shareholders will have a reason to smile today, with the analysts making...

Market forces rained on the parade of NetDragon Websoft Holdings Limited ( HKG:777 ) shareholders today, when the...

One thing we could say about the analysts on West China Cement Limited ( HKG:2233 ) - they aren't optimistic, having...

Jiaxin International Resources Investment Limited ( HKG:3858 ) shareholders will have a reason to smile today, with the...

Recent share performance and business snapshot Ascentage Pharma Group International (SEHK:6855) has drawn investor attention after recent share price moves, with returns of about 13% over the past week and 15% over the past month. The Suzhou based clinical stage biotech focuses on therapies for cancers, chronic hepatitis B and age related diseases in Mainland China. It generated HK$574.12 million in revenue and reported a net loss of HK$1,242.77 million. See our latest analysis for Ascentage...

Why Angelalign Technology’s latest earnings and dividends matter for investors Angelalign Technology (SEHK:6699) has drawn fresh attention after releasing full year 2025 earnings, alongside a proposed special dividend of HK$4.99 per share and affirming its regular annual payout. See our latest analysis for Angelalign Technology. Since these results and dividend announcements, the share price has gained momentum, with a 30 day share price return of 11.71%, a year to date share price return of...

Those following along with Shenzhou International Group Holdings Limited ( HKG:2313 ) will no doubt be intrigued by the...

The market seemed underwhelmed by last week's earnings announcement from Guangdong Kanghua Healthcare Group Co., Ltd...

The recent earnings posted by China Hongguang Holdings Limited ( HKG:8646 ) were solid, but the stock didn't move as...

As global markets navigate the complexities of Middle East tensions and energy market volatility, Asian small-cap stocks present intriguing opportunities amid a backdrop of mixed economic signals. With key indices showing resilience and geopolitical uncertainties influencing investor sentiment, identifying promising small-cap companies requires a focus on those with robust fundamentals and strategic insider actions that align with current market dynamics.

The analysts covering C&D International Investment Group Limited ( HKG:1908 ) delivered a dose of negativity to...

The market was pleased with the recent earnings report from Chaoju Eye Care Holdings Limited ( HKG:2219 ), despite the...

FWD Group Holdings: recent performance snapshot FWD Group Holdings (SEHK:1828) has drawn investor attention after recent share price moves, with the stock showing mixed short term returns and a last close of HK$31.18 on the Hong Kong market. See our latest analysis for FWD Group Holdings. Recent trading has been choppy, with a 1 day share price return of 1.52% decline and a 7 day share price return of 2.63% gain, set against a 30 day share price return of 10.66% decline and a year to date...

Bank of China Limited reported its full-year 2025 results, with net interest income of CNY 440.71 billion and net income of CNY 243.02 billion, and the board recommended a 2025 final dividend of CNY 1.169 per 10 shares, subject to shareholder approval. The bank also confirmed Ms. Huang Xueling’s appointment as Executive Vice President in late March 2026, highlighting ongoing leadership renewal alongside a higher proposed cash return to shareholders. We’ll now examine how the higher proposed...

Geely Automobile Holdings (SEHK:175) is back in focus after Volvo Cars and Geely Auto signed a memorandum of understanding that would make Volvo the exclusive importer and commercial operator for Lynk & Co vehicles in Europe. See our latest analysis for Geely Automobile Holdings. The memorandum of understanding appears to have arrived at a time when momentum in Geely Automobile Holdings' shares has been strong, with a 1 month share price return of 45.60% and a year to date share price return...

Why AIA Group Is Back on Investors’ Radar AIA Group (SEHK:1299) has attracted fresh attention after a year total return of 66.5%. This has prompted investors to reassess its HK$901.1b valuation, recent share performance and fundamentals. See our latest analysis for AIA Group. While the latest 1 day share price return of 1.54% is negative and short term moves have been mixed, the 1 year total shareholder return of 66.54% points to stronger momentum building over a longer horizon around AIA...

If you are wondering whether BYD’s current share price reflects its true worth, the recent mix of returns gives plenty to think about. The stock is recently trading at HK$103.9, with a 9.7% gain over 30 days, a 5.2% return year to date, but a 4.6% decline over the last year and a 41.1% and 91.3% return over 3 and 5 years respectively. These moves sit against a backdrop of ongoing investor interest in the electric vehicle and battery space. Sentiment can shift quickly as policies,...